Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.

Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.
复制标题

DOI:
10.1126/sciimmunol.abj2901
复制
发表时间:
2021-10-15
期刊:
影响因子:
24.8
通讯作者:
Alter G
Alter G
中科院分区:
医学1区
文献类型:
--
作者:
Kaplonek P;Wang C;Bartsch Y;Fischinger S;Gorman MJ;Bowman K;Kang J;Dayal D;Martin P;Nowak RP;Villani AC;Hsieh CL;Charland NC;Gonye ALK;Gushterova I;Khanna HK;LaSalle TJ;Lavin-Parsons KM;Lilley BM;Lodenstein CL;Manakongtreecheep K;Margolin JD;McKaig BN;Rojas-Lopez M;Russo BC;Sharma N;Tantivit J;Thomas MF;Sade-Feldman M;Feldman J;Julg B;Nilles EJ;Musk ER;Menon AS;Fischer ES;McLellan JS;Schmidt A;Goldberg MB;Filbin MR;Hacohen N;Lauffenburger DA;Alter G

文献摘要

参考文献

被引文献

相似文献

先前存在的跨冠状病毒免疫影响COVID-19后SARS-CoV-2体液免疫的早期发展。对SARS-CoV-2感染的保护有许多相关因素,但目前尚不清楚先前建立的对常见季节性冠状病毒的免疫反应如何与COVID-19保护相关。在这里,Kaplonek和Wang等人研究了无症状、中度、重度或致命疾病的COVID-19患者血液中对SARS-CoV-2和普通感冒β-冠状病毒OC43的早期抗体反应。他们发现,在COVID-19存活并经历较轻疾病的患者中,对SARS-CoV-2的初始抗体反应与针对OC43的抗体相关。因此,这项研究表明,对常见季节性冠状病毒的免疫力可能有助于预防SARS-CoV-2感染。疫苗的引入为抗击SARS-CoV-2带来了希望。然而,在缺乏有效抗病毒药物的情况下,病毒变体的出现使世界与这种疾病的不确定性作斗争。抗体目前代表了对SARS-CoV-2免疫的最强相关性,因此我们在大量急性患者(幸存者和非幸存者)和轻度或无症状的COVID-19个体中分析了最早的体液特征。尽管COVID-19幸存者的sars - cov -2特异性免疫反应发展迅速,但非幸存者表现出迟钝和延迟的体液免疫进化,特别是针对s2特异性抗体。考虑到S2在β-冠状病毒中的保守性,我们发现sars - cov -2特异性免疫的早期发展与幸存者中预先存在的普通β-冠状病毒OC43体液免疫同时发生,这种免疫在无症状感染的个体中也有选择性地扩大。这些数据表明,交叉冠状病毒免疫与预防COVID-19相关,具有重要意义。
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral immunity after COVID-19. There are many correlates of protection to SARS-CoV-2 infection, but it is unclear how previously established immune responses to common seasonal coronaviruses might correlate to COVID-19 protection. Here, Kaplonek and Wang et al. looked at the early antibody responses to SARS-CoV-2 and the common cold β-coronavirus OC43 in the blood of COVID-19 patients with asymptomatic, moderate, severe, or deadly disease. They found that initial antibody responses to SARS-CoV-2 correlated with antibodies against OC43 in patients who survived COVID-19 and experienced milder disease. Thus, this work suggests that immunity to common seasonal coronaviruses may help to protect against SARS-CoV-2 infection. The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2–specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across β-coronaviruses, we found that the early development of SARS-CoV-2–specific immunity occurred in tandem with preexisting common β-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
离散的 SARS-CoV-2 抗体滴度与功能性体液稳定性保持一致。
DOI: 10.1038/s41467-021-21336-8
发表时间: 2021-02-15
影响因子: 16.6
作者:
Bartsch YC;Fischinger S;Siddiqui SM;Chen Z;Yu J;Gebre M;Atyeo C;Gorman MJ;Zhu AL;Kang J;Burke JS;Slein M;Gluck MJ;Beger S;Hu Y;Rhee J;Petersen E;Mormann B;Aubin MS;Hasdianda MA;Jambaulikar G;Boyer EW;Sabeti PC;Barouch DH;Julg BD;Musk ER;Menon AS;Lauffenburger DA;Nilles EJ;Alter G
通讯作者: Alter G
DOI: 10.1016/j.xcrm.2021.100290
发表时间: 2021-06-15
期刊: Cell reports. Medicine
影响因子: --
作者:
Anand SP;Prévost J;Nayrac M;Beaudoin-Bussières G;Benlarbi M;Gasser R;Brassard N;Laumaea A;Gong SY;Bourassa C;Brunet-Ratnasingham E;Medjahed H;Gendron-Lepage G;Goyette G;Gokool L;Morrisseau C;Bégin P;Martel-Laferrière V;Tremblay C;Richard J;Bazin R;Duerr R;Kaufmann DE;Finzi A
通讯作者: Finzi A
DOI: 10.1016/j.clim.2020.108651
发表时间: 2021-03
期刊: Clinical immunology (Orlando, Fla.)
影响因子: --
作者:
Gasmi A;Peana M;Pivina L;Srinath S;Gasmi Benahmed A;Semenova Y;Menzel A;Dadar M;Bjørklund G
通讯作者: Bjørklund G
DOI: 10.3389/fimmu.2020.01120
发表时间: 2020-06-05
影响因子: 7.3
作者:
Fierz, Walter;Walz, Brigitte
通讯作者: Walz, Brigitte
DOI: 10.1126/sciimmunol.abe5511
发表时间: 2020-10-08
期刊: Science immunology
影响因子: 24.8
作者:
Isho B;Abe KT;Zuo M;Jamal AJ;Rathod B;Wang JH;Li Z;Chao G;Rojas OL;Bang YM;Pu A;Christie-Holmes N;Gervais C;Ceccarelli D;Samavarchi-Tehrani P;Guvenc F;Budylowski P;Li A;Paterson A;Yue FY;Marin LM;Caldwell L;Wrana JL;Colwill K;Sicheri F;Mubareka S;Gray-Owen SD;Drews SJ;Siqueira WL;Barrios-Rodiles M;Ostrowski M;Rini JM;Durocher Y;McGeer AJ;Gommerman JL;Gingras AC
通讯作者: Gingras AC